194 related articles for article (PubMed ID: 32440015)
1. Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies.
Imahashi N; Terakura S; Kondo E; Kako S; Uchida N; Kobayashi H; Inamoto Y; Sakai H; Tanaka M; Ishikawa J; Kozai Y; Matsuoka KI; Kimura T; Fukuda T; Atsuta Y; Kanda J;
Bone Marrow Transplant; 2020 Nov; 55(11):2098-2108. PubMed ID: 32440015
[TBL] [Abstract][Full Text] [Related]
2. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
3. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
[TBL] [Abstract][Full Text] [Related]
4. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience.
Alkhaldi H; Goloubeva O; Rapoport AP; Dahiya S; Pang Y; Ali MM; Hardy NM; Mohindra P; Bukhari A; Lutfi F; Sanchez-Petitto G; Molitoris J; Samanta S; Li X; Toth T; Landau M; Hodges S; Nishioka J; Ruehle K; Ridge L; Gahres N; Kocoglu MH; Atanackovic D; Malinou JN; Yared JA
Transplant Proc; 2023; 55(1):214-224. PubMed ID: 36635141
[TBL] [Abstract][Full Text] [Related]
6. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.
Yamada Y; Ikegawa S; Najima Y; Atsuta Y; Konuma R; Adachi H; Wada A; Kishida Y; Konishi T; Nagata A; Kaito S; Nagata R; Noguchi Y; Marumo A; Mukae J; Inamoto K; Toya T; Igarashi A; Kobayashi T; Sakamaki H; Ohashi K; Doki N
Int J Hematol; 2022 Feb; 115(2):244-254. PubMed ID: 34652634
[TBL] [Abstract][Full Text] [Related]
7. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
8. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.
Zhou Z; Nath R; Cerny J; Wang HL; Zhang MJ; Abdel-Azim H; Agrawal V; Ahmed G; Al-Homsi AS; Aljurf M; Alkhateeb HB; Assal A; Bacher U; Bajel A; Bashir Q; Battiwalla M; Bhatt VR; Byrne M; Cahn JY; Cairo M; Choe H; Copelan E; Cutler C; Damlaj MB; DeFilipp Z; De Lima M; Diaz MA; Farhadfar N; Foran J; Freytes CO; Gerds AT; Gergis U; Grunwald MR; Gul Z; Hamadani M; Hashmi S; Hertzberg M; Hildebrandt GC; Hossain N; Inamoto Y; Isola L; Jain T; Kamble RT; Khan MW; Kharfan-Dabaja MA; Kebriaei P; Kekre N; Khera N; Lazarus HM; Liesveld JL; Litzow M; Liu H; Marks DI; Martino R; Mathews V; Mishra A; Murthy HS; Nagler A; Nakamura R; Nathan S; Nishihori T; Olin R; Olsson RF; Palmisiano N; Patel SS; Patnaik MM; Pawarode A; Perales MA; Politikos I; Popat U; Rizzieri D; Sandmaier BM; Savani BN; Seo S; Shah NN; Uy GL; Valcárcel D; Verdonck LF; Waller EK; Wang Y; Weisdorf D; Wirk B; Wong E; Yared JA; Saber W
Blood Adv; 2020 Jul; 4(13):3180-3190. PubMed ID: 32663298
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
10. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.
Wang YH; Tien FM; Tsai CH; Huang HH; Liu JH; Liao XW; Tang JL; Yao M; Ko BS
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1488. PubMed ID: 34196132
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
12. [The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
Tang B; Zheng C; Liu H; Zhu X; Geng L; Wang X; Ding K; Yao W; Tong J; Song K; Zhang L; Qiang P; Zhang X; Sun Z
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):191-5. PubMed ID: 26926370
[TBL] [Abstract][Full Text] [Related]
13. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
Abdelaty MM; Gawaly A; Fathy GM; Kabbash I; Taha A
J Egypt Natl Canc Inst; 2020 Jun; 32(1):28. PubMed ID: 32537680
[TBL] [Abstract][Full Text] [Related]
14. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
[TBL] [Abstract][Full Text] [Related]
15. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
[TBL] [Abstract][Full Text] [Related]
17. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.
Sharma P; Pollyea DA; Smith CA; Purev E; Kamdar M; Haverkos B; Sherbenou D; Rabinovitch R; Hammes A; Gutman JA
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1671-1677. PubMed ID: 29684565
[TBL] [Abstract][Full Text] [Related]
18. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
[TBL] [Abstract][Full Text] [Related]
19. Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia G; Labopin M; Mielke S; Ruggeri A; Nur Ozkurt Z; Bourhis JH; Rabitsch W; Yakoub-Agha I; Grillo G; Sanz J; Arcese W; Novis Y; Fegueux N; Spyridonidis A; Giebel S; Nagler A; Ciceri F; Mohty M
Transplant Cell Ther; 2024 Jan; 30(1):95.e1-95.e10. PubMed ID: 37816471
[TBL] [Abstract][Full Text] [Related]
20. Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil.
Sakatoku K; Kim SW; Okamura H; Kanaya M; Kato K; Yamasaki S; Uchida N; Kobayashi H; Fukuda T; Takayama N; Ishikawa J; Nakazawa H; Sakurai M; Ikeda T; Kondo T; Yoshioka S; Miyamoto T; Kimura T; Ichinohe T; Atsuta Y; Kondo E
Ann Hematol; 2022 Dec; 101(12):2743-2757. PubMed ID: 36195679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
